retatrutide 2025 trial results Timeline: Week-by-Week (48 Weeks) Retatrutide, Eli Lilly's Next-Gen Obesity

The Exercise Synergy involves beginning with what seems manageable and then incrementally increasing as the body becomes stronger and more accustomed to motion

Documentation availability depends on product, batch, and order requirements

Retatrutide has demonstrated potent effects in clinical trials, outperforming current GLP-1 and GIP receptor agonists by promoting higher weight loss percentages and better glycemic control

These datasets are the standard reference points for researchers modelling triple-agonist pharmacology against single- and dual-receptor comparators

Retatrutide also shows potent glucose-lowering effects

Analysts project retatrutide could add $15+ billion annually within three years of launch, and the combined GLP-1 franchise is projected to reach $101 billion in peak annual sales